Genome Editing Redefines Precision Medicine in the Cardiovascular Field

Genome editing is a powerful tool to study the function of specific genes and proteins important for development or disease. Recent technologies, especially CRISPR/Cas9 which is characterized by convenient handling and high precision, revolutionized the field of genome editing. Such tools have enormous potential for basic science as well as for regenerative medicine. Nevertheless, there are still several hurdles that have to be overcome, but patient-tailored therapies, termed precision medicine, seem to be within reach. In this review, we focus on the achievements and limitations of genome editing in the cardiovascular field. We explore different areas of cardiac research and highlight the most important developments: (1) the potential of genome editing in human pluripotent stem cells in basic research for disease modelling, drug screening, or reprogramming approaches and (2) the potential and remaining challenges of genome editing for regenerative therapies. Finally, we discuss social and ethical implications of these new technologies.

[1]  Nicole M. Gaudelli,et al.  Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage , 2017, Nature.

[2]  Max A. Horlbeck,et al.  Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation , 2014, Cell.

[3]  Ying Sun,et al.  CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes , 2015, Protein & Cell.

[4]  Y. Doyon,et al.  Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme , 2012, Genome research.

[5]  George Church,et al.  Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy , 2015, Science.

[6]  Mengmeng Gong,et al.  CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein , 2017, Molecular Genetics and Genomics.

[7]  M. Ohkura,et al.  Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts , 2016, Nature.

[8]  Lei Wang,et al.  Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos , 2014, Cell.

[9]  M. Hasegawa,et al.  Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome , 2009, Proceedings of the Japan Academy. Series B, Physical and biological sciences.

[10]  G. Church,et al.  Efficient construction of sequence-specific TAL effectors for modulating mammalian transcription. , 2011, Nature biotechnology.

[11]  Robert L Wilensky,et al.  A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. , 2006, European heart journal.

[12]  Sean M. Wu,et al.  Untangling the Biology of Genetic Cardiomyopathies with Pluripotent Stem Cell Disease Models , 2017, Current Cardiology Reports.

[13]  C. Mummery,et al.  Subtype-specific promoter-driven action potential imaging for precise disease modelling and drug testing in hiPSC-derived cardiomyocytes. , 2016, European heart journal.

[14]  E. Tartour,et al.  Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. , 2015, European heart journal.

[15]  M. Mann,et al.  Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy , 2015, EMBO molecular medicine.

[16]  Hui Zhao,et al.  Direct activation of human and mouse Oct4 genes using engineered TALE and Cas9 transcription factors , 2014, Nucleic acids research.

[17]  Kun Zhang,et al.  Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. , 2014, Cell stem cell.

[18]  C. Mummery,et al.  Subtype-specific promoter-driven action potential imaging for precise disease modelling and drug testing in hiPSC-derived cardiomyocytes , 2016, European heart journal.

[19]  N. Benvenisty,et al.  Quality control Genome maintenance in pluripotent stem cells , 2014 .

[20]  George A. Truskey,et al.  Modeling the mitochondrial cardiomyopathy of Barth syndrome with iPSC and heart-on-chip technologies , 2014, Nature Medicine.

[21]  L. García,et al.  Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice , 2013, EMBO molecular medicine.

[22]  K. Pollard,et al.  Human Disease Modeling Reveals Integrated Transcriptional and Epigenetic Mechanisms of NOTCH1 Haploinsufficiency , 2015, Cell.

[23]  J. Keith Joung,et al.  Improving CRISPR-Cas nuclease specificity using truncated guide RNAs , 2014, Nature Biotechnology.

[24]  M. Horie,et al.  Allele‐specific ablation rescues electrophysiological abnormalities in a human iPS cell model of long‐QT syndrome with a CALM2 mutation , 2017, Human molecular genetics.

[25]  Ronald A. Li,et al.  Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy , 2015, Nature Communications.

[26]  J. Keith Joung,et al.  High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells , 2013, Nature Biotechnology.

[27]  Jacob E Corn,et al.  Enhancing homology-directed genome editing by catalytically active and inactive CRISPR-Cas9 using asymmetric donor DNA , 2016, Nature Biotechnology.

[28]  Martin J. Aryee,et al.  GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases , 2014, Nature Biotechnology.

[29]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[30]  David A. Brafman,et al.  May I Cut in? Gene Editing Approaches in Human Induced Pluripotent Stem Cells , 2017, Cells.

[31]  Kevin T. Zhao,et al.  Increasing the genome-targeting scope and precision of base editing with engineered Cas9-cytidine deaminase fusions , 2017, Nature Biotechnology.

[32]  Charles E. Murry,et al.  Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate Non-Human Primate Hearts , 2014, Nature.

[33]  T. Doetschman,et al.  muscular dystrophies Gene Editing With CRISPR / Cas 9 RNA-Directed Nuclease , 2017 .

[34]  Simona Casini,et al.  Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome , 2013, The EMBO journal.

[35]  A. Hendel,et al.  A Comprehensive TALEN-Based Knockout Library for Generating Human-Induced Pluripotent Stem Cell–Based Models for Cardiovascular Diseases , 2017, Circulation research.

[36]  M. Kay,et al.  Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. , 2014, Journal of the American College of Cardiology.

[37]  David A. Scott,et al.  Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Editing Specificity , 2013, Cell.

[38]  International Human Genome Sequencing Consortium.  Initial sequencing and analysis of the human genome , 2001, Nature.

[39]  Steve D. M. Brown,et al.  Correction of the auditory phenotype in C57BL/6N mice via CRISPR/Cas9-mediated homology directed repair , 2016, Genome Medicine.

[40]  G. Fishman,et al.  Identification and Purification of Human Induced Pluripotent Stem Cell-Derived Atrial-Like Cardiomyocytes Based on Sarcolipin Expression , 2014, PloS one.

[41]  Martin J. Aryee,et al.  Engineered CRISPR-Cas9 nucleases with altered PAM specificities , 2015, Nature.

[42]  J. Joung,et al.  Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition , 2015, Nature Biotechnology.

[43]  B. Li,et al.  Expression profiling reveals off-target gene regulation by RNAi , 2003, Nature Biotechnology.

[44]  D. Malan,et al.  Differential Expression Levels of Integrin α6 Enable the Selective Identification and Isolation of Atrial and Ventricular Cardiomyocytes , 2015, PloS one.

[45]  Richard L. Frock,et al.  Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases , 2014, Nature Biotechnology.

[46]  Denise E. Waldron.  Gene therapy: In vivo gene editing in non-dividing cells , 2017, Nature Reviews Genetics.

[47]  George M. Church,et al.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.

[48]  Desheng Liang,et al.  TALE nickase mediates high efficient targeted transgene integration at the human multi-copy ribosomal DNA locus. , 2014, Biochemical and biophysical research communications.

[49]  John M. Shelton,et al.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.

[50]  A. Haverich,et al.  Transplantation of purified iPSC-derived cardiomyocytes in myocardial infarction , 2017, PloS one.

[51]  Yarden Katz,et al.  Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system , 2013, Cell Research.

[52]  Terran Lane,et al.  A computational study of off-target effects of RNA interference , 2005, Nucleic acids research.

[53]  David R. Liu,et al.  Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage , 2016, Nature.

[54]  K. Maher,et al.  Molecular beacon-based detection and isolation of working-type cardiomyocytes derived from human pluripotent stem cells. , 2015, Biomaterials.

[55]  J. Keith Joung,et al.  731. High-Fidelity CRISPR-Cas9 Nucleases with No Detectable Genome-Wide Off-Target Effects , 2016 .

[56]  Sara Mantero,et al.  Clinical transplantation of a tissue-engineered airway , 2008, The Lancet.

[57]  Edward M. Callaway,et al.  In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration , 2016, Nature.

[58]  J. C. Tsang,et al.  Reprogramming to Pluripotency Using Designer TALE Transcription Factors Targeting Enhancers , 2013, Stem cell reports.

[59]  Michael P Snyder,et al.  iPSC-derived cardiomyocytes reveal abnormal TGFβ signaling in left ventricular non-compaction cardiomyopathy , 2016, Nature Cell Biology.

[60]  S. Yamanaka,et al.  Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.

[61]  Hans Clevers,et al.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.

[62]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[63]  Yuki Masumura,et al.  Targeted Genome Replacement via Homology-directed Repair in Non-dividing Cardiomyocytes , 2017, Scientific Reports.

[64]  C. Mason,et al.  A brief definition of regenerative medicine. , 2008, Regenerative medicine.

[65]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[66]  Chad A. Cowan,et al.  Genome-Edited Human Pluripotent Stem Cell–Derived Macrophages as a Model of Reverse Cholesterol Transport—Brief Report , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[67]  Johan Verjans,et al.  Myocardial remodeling after infarction: the role of myofibroblasts , 2010, Nature Reviews Cardiology.

[68]  R. Ramirez,et al.  Myosin light chain 2-based selection of human iPSC-derived early ventricular cardiac myocytes. , 2013, Stem cell research.

[69]  ジョン，ジェー．キース,et al.  Engineered CRISPR-Cas9 nucleases with altered PAM specificity , 2016 .

[70]  Dongsheng Duan,et al.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.

[71]  G. Church,et al.  CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering , 2013, Nature Biotechnology.

[72]  Christopher M. Vockley,et al.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.

[73]  C. Robertson,et al.  Concise Review: Maturation Phases of Human Pluripotent Stem Cell‐Derived Cardiomyocytes , 2013, Stem cells.

[74]  M. Hoehn,et al.  Bioluminescent Imaging of Genetically Selected Induced Pluripotent Stem Cell-Derived Cardiomyocytes after Transplantation into Infarcted Heart of Syngeneic Recipients , 2014, PloS one.

[75]  C. Antos,et al.  Making human cardiomyocytes up to date: Derivation, maturation state and perspectives. , 2017, International journal of cardiology.

[76]  Charles A. Gersbach,et al.  A CRISPR/Cas9-Based System for Reprogramming Cell Lineage Specification , 2014, Stem cell reports.

[77]  Rudolf Jaenisch,et al.  One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.

[78]  Alain Bel,et al.  Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. , 2015, European heart journal.

[79]  Jianhui Gong,et al.  Correction of a pathogenic gene mutation in human embryos , 2018, Yearbook of Paediatric Endocrinology.

[80]  Daniel J. Rader,et al.  Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing , 2014, Circulation research.

[81]  H. Leonhardt,et al.  Targeted transcriptional activation of silent oct4 pluripotency gene by combining designer TALEs and inhibition of epigenetic modifiers , 2012, Nucleic acids research.

[82]  Gang Bao,et al.  CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity , 2013, Nucleic acids research.